Development of a Prognostic Nomogram for Liver Metastasis of Uveal Melanoma Patients Selected by Liver MRI.

liver MRI liver metastasis prognostic factors tumour burden uveal melanoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 Jun 2019
Historique:
received: 05 05 2019
revised: 17 06 2019
accepted: 19 06 2019
entrez: 26 6 2019
pubmed: 27 6 2019
medline: 27 6 2019
Statut: epublish

Résumé

Patients with liver metastases of uveal melanoma (LMUM) die from their metastatic evolution within 2 years. We established a nomogram to choose a treatment adapted to life expectancy. From 2002 to 2013, we reviewed 224 patients with LMUM selected by liver MRI. A nomogram was developed based on a Cox model. The predictive performance of the model was assessed according to the C-statistic, Kaplan-Meier curve, and calibration plots. The median follow-up was 49.2 months (range, 0.6-70.9). The survival rates at 6, 12, and 24 months were 0.88 (0.95 CI [0.84-0.93]), 0.68 (0.95 CI [0.62-0.75]), and 0.26 (0.95 CI [0.21-0.33]), respectively. The four factors selected for the nomogram with a worse prognosis were: A disease-free interval between the UM and LMUM groups of less than 6 months (HR = 3.39; 0.95 CI [1.90-6.05]), more than 10 LMUM (HR = 3.95; 0.95 CI [1.97-4.43]), a maximum LMUM of more than 1200 mm2 (HR = 2.47; 0.95 CI [1.53-3.98]), and a lactate dehydrogenase (LDH) value greater than 1.5 (HR = 3.72; 0.95 CI [2.30-6.00]). The model achieved relatively good discrimination and calibration (C-statistic 0.71). This nomogram could be useful for decision-making and risk stratification for therapeutic options.

Identifiants

pubmed: 31234340
pii: cancers11060863
doi: 10.3390/cancers11060863
pmc: PMC6627813
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancer. 2003 Jan 15;97(2):465-75
pubmed: 12518371
Cancer. 2004 Jan 1;100(1):122-9
pubmed: 14692032
Cancer Res. 2004 Oct 15;64(20):7205-9
pubmed: 15492234
Graefes Arch Clin Exp Ophthalmol. 2005 Oct;243(10):985-93
pubmed: 15891893
J Clin Oncol. 2005 Nov 1;23(31):8076-80
pubmed: 16258106
Arch Ophthalmol. 2005 Dec;123(12):1639-43
pubmed: 16344433
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2572-80
pubmed: 19151381
Eur J Surg Oncol. 2009 Nov;35(11):1192-7
pubmed: 19329272
Ophthalmology. 1991 Mar;98(3):383-9; discussion 390
pubmed: 2023760
AJR Am J Roentgenol. 2010 Aug;195(2):281-9
pubmed: 20651182
Radiology. 2010 Dec;257(3):674-84
pubmed: 20829538
Eur J Radiol. 2012 Apr;81(4):683-91
pubmed: 21316886
Melanoma Res. 2011 Jun;21(3):217-22
pubmed: 21467954
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Dev Ophthalmol. 2012;49:166-181
pubmed: 22042020
Eur J Cancer. 2012 May;48(8):1167-75
pubmed: 22119735
Clin Cancer Res. 2012 Jul 15;18(14):3934-41
pubmed: 22645051
Open Ophthalmol J. 2012;6:49-53
pubmed: 22798969
J Clin Oncol. 2013 Aug 1;31(22):2825-31
pubmed: 23816968
Mod Pathol. 2014 Feb;27(2):175-83
pubmed: 23887304
Int J Cancer. 2014 Mar 1;134(5):1207-13
pubmed: 23934701
Ann Surg Oncol. 2014 Feb;21(2):466-72
pubmed: 24141377
Br J Ophthalmol. 2014 Jun;98(6):769-74
pubmed: 24169649
J Surg Oncol. 2014 May;109(6):542-7
pubmed: 24357463
Semin Intervent Radiol. 2013 Mar;30(1):39-48
pubmed: 24436516
Ann Oncol. 2014 Mar;25(3):742-6
pubmed: 24510314
Eur Radiol. 2015 Aug;25(8):2263-73
pubmed: 25712144
PLoS One. 2015 Mar 17;10(3):e0120181
pubmed: 25780931
Pigment Cell Melanoma Res. 2016 Jan;29(1):60-7
pubmed: 26523470
Ann Surg Oncol. 2016 Apr;23(4):1327-34
pubmed: 26628434
Eur J Surg Oncol. 2016 May;42(5):706-12
pubmed: 26968227
Am J Ophthalmol. 2016 Aug;168:217-226
pubmed: 27296487
Br J Ophthalmol. 2017 Jan;101(1):38-44
pubmed: 27574175
Cancer Med. 2017 Jul;6(7):1581-1586
pubmed: 28639409
Cancer Res Treat. 2018 Oct;50(4):1130-1139
pubmed: 29198096
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
Clin Cancer Res. 2018 Oct 15;24(20):4915-4917
pubmed: 29903895
Cancer. 1981 Jan 1;47(1):207-14
pubmed: 7459811
Chirurgie. 1993-1994;119(6-7):354-6
pubmed: 7805494
Cancer. 1995 Nov 1;76(9):1665-70
pubmed: 8635073

Auteurs

Pascale Mariani (P)

Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75248 Cedex 05 Paris, France. pascale.mariani@curie.fr.

Sylvain Dureau (S)

Department of Biostatistic, Institut Curie, 26 rue d'Ulm, 75248 Cedex 05 Paris, France. sylvain.dureau@curie.fr.

Alexia Savignoni (A)

Department of Biostatistic, Institut Curie, 26 rue d'Ulm, 75248 Cedex 05 Paris, France. alexia.savignoni@curie.fr.

Livia Lumbroso-Le Rouic (LL)

Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75248 Cedex 05 Paris, France. livia.lumbroso@curie.fr.

Christine Levy-Gabriel (C)

Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75248 Cedex 05 Paris, France. christine.levy@curie.fr.

Sophie Piperno-Neumann (S)

Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75248 Cedex 05 Paris, France. sophie.piperno-neumann@curie.fr.

Manuel J Rodrigues (MJ)

Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75248 Cedex 05 Paris, France. manuel.rodrigues@curie.fr.

Laurence Desjardins (L)

Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75248 Cedex 05 Paris, France. laurence.desjardins@curie.fr.

Nathalie Cassoux (N)

Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75248 Cedex 05 Paris, France. nathalie.cassoux@curie.fr.

Vincent Servois (V)

Department of Radiology, Institut Curie, 26 rue d'Ulm, 75248 Cedex 05 Paris, France. vincent.servois@curie.fr.

Classifications MeSH